Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Baxter
Cipla
Julphar
AstraZeneca
US Department of Justice
Express Scripts
Johnson and Johnson

Generated: October 17, 2018

DrugPatentWatch Database Preview

BELVIQ Drug Profile

« Back to Dashboard

Which patents cover Belviq, and when can generic versions of Belviq launch?

Belviq is a drug marketed by Eisai Inc and is included in two NDAs. There are fifteen patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lorcaserin hydrochloride profile page.

Drug patent expirations by year for BELVIQ
Synonyms for BELVIQ
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride--water (2/1)
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinium chloride
(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine
(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride
(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride hemihydrate
(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(R)-1h-3-benzazepine,8-chloro-2,3,4,5-tetrahydro-1-methyl-,hydrochloride
(R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hemihydrate hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
(r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride salt
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride salt hemihydrate
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine
(R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine dihydrochloride hydrate
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride hemihydrate
0QJF08GDPE
10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene
1H-3-Benzazepine, 8-chloro-2,3,4,5-tetrahydro-1-methyl-, (1R)-
1H-3-Benzazepine, 8-chloro-2,3,4,5-tetrahydro-1-methyl-, hydrochloride, hydrate (2:2:1), (1R)-
202L927
616202-92-7
637E494O0Z
846589-98-8
AB0080320
AB0148401
AB52744
AC-8945
ACN-036083
ACT10402
AJ-56780
AK101075
AK142745
AK165594
AKOS005145786
AKOS006326204
AKOS025395692
AM81248
AN-6779
AN-7508
ANW-60436
AOB87116
APD 356
APD-356
APD356
API0005054
AR-10A
AX8136671
BC224447
BC224451
BCP9000859
BDBM50161646
Belvig
Belviq (TN)
Belviq Xr
CAS-616202-92-7
CHEBI:65350
CHEBI:65353
CHEBI:66852
CHEMBL2095211
CHEMBL360328
CS-0752
CS-1232
CTK8B8482
D01JMC
D06613
DB04871
DSSTox_CID_28585
DSSTox_GSID_48659
DSSTox_RID_82856
DTXSID3048659
DTXSID60233650
EX-A1697
FCH873876
FT-0670852
FT-0696346
FT-0699079
GTPL2941
HE113886
HSDB 8128
HY-11093
HY-15368
ITIHHRMYZPNGRC-QRPNPIFTSA-N
KS-0000006Z
KS-1439
Lorcaserin
Lorcaserin (Hydrochloride)
Lorcaserin [INN]
Lorcaserin HCl
Lorcaserin hydrochloride
Lorcaserin hydrochloride (USAN)
Lorcaserin hydrochloride [USAN]
Lorcaserin hydrochloride hemihydrate
Lorcaserin hydrochloride(APD-356)
Lorcaserin;
Lorqess
MFCD09833667
MolPort-005-942-404
NCGC00182550-01
NCGC00182550-02
QC-9041
REV26SR2B4
SCHEMBL169382
SCHEMBL173899
ST24035516
Tox21_113018
Tox21_113018_1
TX-017673
UNII-0QJF08GDPE
UNII-637E494O0Z
UNII-REV26SR2B4
W-5408
W-5409
WRZCAWKMTLRWPR-VSODYHHCSA-N
XTTZERNUQAFMOF-QMMMGPOBSA-N
ZINC6733300

US Patents and Regulatory Information for BELVIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BELVIQ
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 20 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Tablets 10 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Baxter
Cipla
Julphar
AstraZeneca
US Department of Justice
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.